Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans
Restricted accessResearch articleFirst published online April, 2013
Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans
According to the International Conference on Harmonisation (ICH) and Food and Drug Administration (FDA) guidelines for paediatric clinical trials, bridging procedures can be used if disease progression, exposure–response relationships, and clinical endpoints are similar in adults and children. In these circumstances, confirmatory efficacy trials are not necessary; the evaluation of pharmacokinetics and safety ought to be sufficient for drug approval.
Purpose
The aim of this study was to assess whether the clinical trials and strategy for market approval authorisation (MAAs) in paediatric indications reflect the guidelines for bridging of adult data.
Methods
A total of 95 European Public Assessment Reports (EPARs) published between 1995 and 2007 were reviewed. From every report, data extraction was performed according to the phase of development, scope of analysis, number of dose levels, dosage form, and demographics of the subjects enrolled in the trial. Data analysis consisted of an initial grouping of the studies by the degree of compliance to bridging guidelines.
Results
Our analysis reveals that only 66% of the trials (n = 174) can be classified as needed, while 22% of the trials (n = 59) could have been designed and performed differently from the approved protocol (partially required). Moreover, 12% (n = 30) of the studies were deemed completely unnecessary.
Limitations
A potential limitation in our study was that the dates of start and completion of the clinical studies were not available. Therefore, some EPARs have been included that may reflect common practice in the period that precedes the introduction of the ICH E11 guidelines. Yet, this should not obscure the points identified with regard to the lack of compliance to guidelines before the introduction of the paediatric legislation and the requirements for a paediatric investigation plan.
Conclusions
Paediatric trials are desirable and necessary to address important unmet medical needs. However, the types of studies supporting regulatory approval do not always reflect the recommendations available in paediatric guidelines, which allow for extrapolation and bridging approaches. This situation may be explained by the lack of awareness about the prerequisites for the use of bridging concepts and of a clear process for evaluating different strategies in paediatric development.
Get full access to this article
View all access options for this article.
References
1.
PinxtenWDierickxKNysH.Ethical principles and legal requirements for pediatric research in the EU: An analysis of the European normative and legal framework surrounding pediatric clinical trials. Eur J Pediatr2009; 168(10): 1225–34.
2.
KapogiannisBGMattisonDR.Adolescents in clinical trials. Clin Pharmacol Ther2008; 84(6): 655–59.
3.
LaventhalNTariniBALantosJ.Ethical issues in neonatal and pediatric clinical trials. Pediatr Clin North Am2012; 59(5): 1205–20.
European Commission. Communication from the Commission – Guidance on the information concerning paediatric clinical trials to be entered into the EU Database on Clinical Trials (EudraCT) and on the information to be made public by the European Medicines Agency (EMA), in accordance with Article 41 of Regulation (EC) N 1901/2006. Available at: http://ec.europa.eu/health/files/eudralex/vol-10/2009_c28_01/2009_c28_01_en.pdf (accessed 11 December 2012).
US Department of Health and Human Services, Food and Drug Administration. Appendix B: Pediatric decision tree integration of PK-PD. Guidance for industry. Exposure–Response Relationships – Study design, data analysis, and regulatory application. 2003.
10.
ReignerBRicciBMLiogierX.Role of clinical Pharmacology in the development of Paediatric Clinical Development Plans. In RoseKVan Den AnkerJ (eds) Guide to Paediatric Drug Development and Clinical Research. Karger, Basel, 2010, pp. 51–59.
11.
JohnsonTN.Modelling approaches to dose estimation in children. Br J Clin Pharmacol2005; 59(6): 663–69.
The Merck Manuals Online Medical Library.PorterRKaplanJ (eds). See sections menu for disease summaries. Available at: http://www.merck.com/mmhe/index.html
58.
SaldienVVermeyenKMWuytsFL.Target-controlled infusion of rocuronium in infants, children, and adults: A comparison of the pharmacokinetic and pharmacodynamic relationship. Anesth Analg2003; 97(1): 44–49.
59.
MarshallJDWellsTGLetzigLKearnsGL.Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients. J Clin Pharmacol1998; 38(11): 994–1002.
60.
OrensteinSRBlumerJLFaesselHM. Ranitidine, 75 mg, over-the-counter dose: Pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther2002; 16(5): 899–907.
61.
WasterlainCGChenJW.Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia2008; 49(Suppl. 9): 63–73.
62.
KirmaniBFCrispEDKayaniSRajabH.Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol2009; 41(1): 37–39.
63.
ØStergaardDGätkeMRBergHRasmussenSNViby-MogensenJ.The pharmacodynamics and pharmacokinetics of mivacurium in children. 2009; 46(5): 512–18.
64.
MarshallJDKearnsGL.Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther1999; 66(1): 66–75.
65.
Abdel-RahmanSMJohnsonFKConnorJD. Developmental pharmacokinetics and pharmacodynamics of nizatidine. J Pediatr Gastroenterol Nutr2004; 38(4): 442–51.
66.
TakahashiHIshikawaSNomotoS. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther2000; 68(5): 541–55.
67.
OlskiTMLampusSFGherarducciGSaintRA.Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol2011; 67(3): 245–52.
68.
DunneJRodriguezWJMurphyMD. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics2011; 128(5): e1242–49.
